Genzyme completes Impath buy:
This article was originally published in Clinica
Executive Summary
Genzyme has completed its $215m cash acquisition of Impath's oncology testing service business, which will become part of its Genzyme Genetics business. The deal brings Genzyme laboratories in New York, Phoenix, Arizona, and Los Angeles, as well as a clinical trial testing facility serving companies developing new drugs. The purchase goes hand in hand with that of cancer drug developer Ilex Oncology in creating a strong oncology offering in both therapeutics and diagnostics at Genzyme. Impath's technology includes molecular diagnostics, flow cytometry, cytogenetics and immunohistochemistry.